Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.4335
+0.0119 (2.82%)
Mar 4, 2026, 1:09 PM EST - Market open
Outlook Therapeutics Employees
Outlook Therapeutics had 17 employees as of September 30, 2025. The number of employees decreased by 6 or -26.09% compared to the previous year.
Employees
17
Change (1Y)
-6
Growth (1Y)
-26.09%
Revenue / Employee
$12,100
Profits / Employee
-$6,050,624
Market Cap
36.01M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 17 | -6 | -26.09% |
| Sep 30, 2024 | 23 | -1 | -4.17% |
| Sep 30, 2023 | 24 | 7 | 41.18% |
| Sep 30, 2022 | 17 | 8 | 88.89% |
| Sep 30, 2021 | 9 | 1 | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Atara Biotherapeutics | 38 |
| Palatin Technologies | 29 |
| Actinium Pharmaceuticals | 25 |
| INmune Bio | 22 |
| ABVC BioPharma | 19 |
| CervoMed | 15 |
OTLK News
- 13 days ago - Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland - GlobeNewsWire
- 15 days ago - Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 21 days ago - Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter - GlobeNewsWire
- 2 months ago - Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - GlobeNewsWire
- 2 months ago - US FDA declines to approve Outlook Therapeutics' eye disease drug - Reuters
- 2 months ago - Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD - GlobeNewsWire
- 2 months ago - Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again - Seeking Alpha
- 2 months ago - Outlook Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire